Insider buying
~$6K5,000 sh @ $1.21
Traded Dec 31, 2024 · filed 3 days later
The CEO of Prelude Therapeutics paid $6K out of pocket for Prelude Therapeutics shares. 2 other people at Prelude Therapeutics bought some too, in the same month.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Dec 23, 2024 · Filed Dec 26, 2024
Prelude Therapeutics's Chief Chemistry Officer paid $82K out of pocket for Prelude Therapeutics shares. 2 other people at Prelude Therapeutics bought some too, in the same month. Shares held went up 19% with this purchase.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$82,002
Shares × reported transaction price
$25K–$100K
+18.9%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
Not enough history to judge
Confirmed open-market purchases by the same insider in the available history
3 distinct insiders in 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
47 days after results of Nov 6, 2024, 77 days before results of Mar 10, 2025
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +3.7% | −0.5% | +4.2% |
| 30 days | −15.7% | +0.7% | −16.4% |
| 90 days | −49.1% | −4.7% | −44.4% |
| 180 days | −36.2% | +2.0% | −38.3% |
| 365 days | +119.4% | +15.6% | +103.8% |
Past results only. Not a forecast.
Insider buying
Traded Dec 31, 2024 · filed 3 days later
The CEO of Prelude Therapeutics paid $6K out of pocket for Prelude Therapeutics shares. 2 other people at Prelude Therapeutics bought some too, in the same month.
Insider buying
Traded Dec 30, 2024 · filed 3 days later
The CEO of Prelude Therapeutics paid $12K out of pocket for Prelude Therapeutics shares. 2 other people at Prelude Therapeutics bought some too, in the same month. Shares held went up 8% with this purchase.
Insider buying
Traded Dec 19, 2024 · filed 1 day later
The CFO of Prelude Therapeutics paid $23K out of pocket for Prelude Therapeutics shares. 2 other people at Prelude Therapeutics bought some too, in the same month. Shares held went up 1042% with this purchase.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.